Dr. Hallenbeck will provide an update on the latest efforts with Multiple IV dosing with SVV-001
PHILADELPHIA–(BUSINESS WIRE)–Seneca Therapeutics, Inc., announced today Dr. Paul Hallenbeck will present a talk titled “Facilitating multiple deliveries of therapeutic viruses by exploiting natural methods of evading neutralizing immunity”, during the World Vaccine Congress in Santa Clara, CA on November 28, 2023. In his talk, Dr. Hallenbeck will present data on the development of multiple IV technology for SVV-001, a clinical stage oncology product.
“Seneca believes that having both multiple intratumoral (‘IT’) and multiple intravenous (‘IV’) dosage forms of SVV-001 will be important to clinicians,” said Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics. “Unlike many oncolytic viruses, SVV-001 has already been safely delivered systemically as a single dose in humans. SVV-001 has also shown efficacy in relevant murine models as a single IV dose and preliminary evidence of efficacy in humans as a single IV dose. We will present data showing several approaches to deliver SVV-001 systemically in a multiple dose IV regimen.”
About Seneca Therapeutics
Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 that create additional anti-tumor effects.
Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.
Contacts
Paul Hallenbeck
CSO and President
phallenbeck@senecatherapeutics.com
James Hussey
CEO
jhussey@senecatherapeutics.com
